摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-(octahydro-quinolin-1(2H)-yl)-[5-(1-pyrimidin-2-yl-piperidin-4-yl)-thiophen-3-yl]-methanone

中文名称
——
中文别名
——
英文名称
cis-(octahydro-quinolin-1(2H)-yl)-[5-(1-pyrimidin-2-yl-piperidin-4-yl)-thiophen-3-yl]-methanone
英文别名
3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-1-yl-[5-(1-pyrimidin-2-ylpiperidin-4-yl)thiophen-3-yl]methanone
cis-(octahydro-quinolin-1(2H)-yl)-[5-(1-pyrimidin-2-yl-piperidin-4-yl)-thiophen-3-yl]-methanone化学式
CAS
——
化学式
C23H30N4OS
mdl
——
分子量
410.583
InChiKey
AGOWHVULFVCADK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    29
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.61
  • 拓扑面积:
    77.6
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS
    [FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
    摘要:
    本发明一般涉及治疗化合物领域。更具体地,本发明涉及某些酰胺噻吩化合物,其中包括抑制11β-羟基类固醇脱氢酶1(11β-HSD1)。本发明还涉及包含这些化合物的药物组合物,以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1;治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病;治疗代谢综合征,其中包括2型糖尿病和肥胖等疾病,以及相关疾病,包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病,如缺血性(冠状)心脏病;治疗中枢神经系统疾病,如轻度认知障碍和早期痴呆,包括阿尔茨海默病等。公式(I)。
    公开号:
    WO2009074789A1
点击查看最新优质反应信息

文献信息

  • Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors
    申请人:Webster Scott Peter
    公开号:US20100267696A1
    公开(公告)日:2010-10-21
    The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
    本发明涉及治疗化合物领域。更具体地,本发明涉及某些酰胺噻吩化合物,其中包括抑制11β-羟基类固醇脱氢酶1型(11β-HSD1)的化合物。本发明还涉及包含这种化合物的制药组合物,以及在体内外使用这种化合物和组合物来抑制11β-羟基类固醇脱氢酶1型,治疗通过抑制11β-羟基类固醇脱氢酶1型改善的疾病,治疗代谢综合征,包括2型糖尿病和肥胖症,以及相关疾病,包括胰岛素抵抗、高血压、脂质异常和缺血性(冠状动脉)心脏病;治疗中枢神经系统疾病,如轻度认知障碍和早期痴呆,包括阿尔茨海默病等。
  • US8362008B2
    申请人:——
    公开号:US8362008B2
    公开(公告)日:2013-01-29
  • [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
    申请人:UNIV EDINBURGH
    公开号:WO2009074789A1
    公开(公告)日:2009-06-18
    The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).
    本发明一般涉及治疗化合物领域。更具体地,本发明涉及某些酰胺噻吩化合物,其中包括抑制11β-羟基类固醇脱氢酶1(11β-HSD1)。本发明还涉及包含这些化合物的药物组合物,以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1;治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病;治疗代谢综合征,其中包括2型糖尿病和肥胖等疾病,以及相关疾病,包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病,如缺血性(冠状)心脏病;治疗中枢神经系统疾病,如轻度认知障碍和早期痴呆,包括阿尔茨海默病等。公式(I)。
查看更多

同类化合物

锯齿石松宁 箭毒蛙毒素 C 坎库碘铵 十氢喹啉 十氢-2-甲基喹啉 八氢对苯二酚-4(1H)-酮 八氢喹啉-2(1H)-酮 八氢-2,6-喹啉二酮 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-10a,12a-二甲基-1,2,3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十六氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 [(4aS,4bR,6aS,8S,10aS,10bS,12aS)-1,10a,12a-三甲基-2-氧代-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢萘并[6,5-f]喹啉-8-基]2-[4-[二(2-氯乙基)氨基]苯基]乙酸酯 8H-13,3,6a-乙基亚基-7,10-亚甲基噁庚并[3,4-i]-1-苯并吖辛因-8-酮,1-乙基十四氢-12a-羟基-6-甲氧基-3-甲基-,(3R,6S,6aS,7R,7aS,10S,12aS,13S,13aR,15R)-(9CI) 8-羟基-十氢喹啉 4-乙炔基-2-甲基十氢喹啉-4-醇 3-羟基-13,17-开环-5-雄甾烯-17-酸-13,17-内酰胺(4-(二(2-氯乙基)氨基)苯基)丁酸酯 2,5-二丙基十氢喹啉 1-(3-氯-丙基)-十氢-喹啉 1,2,2-三甲基-八氢-喹啉-4-酮 (4aS,4bR,8S,10aR,10bS,12aS)-10a,12a-二甲基-2-羰基-1,2,3,4,4a,4b,5,7,8,9,10,10a,10b,11,12,12a-十六氢萘并[2,1-f]喹啉-8-基{4-[二(2-氯乙基)氨基]苯基}乙酸酯 (4aS,4bR,6aS,8S,10aS,10bS,12aS)-8-羟基-10a,12a-二甲基-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-十四氢-1H-萘并[2,1-f]喹啉-2-酮 (3S,13R)-1,2,3,4,4aalpha,5,11,11aalpha-八氢-2,2,5-三甲基-3beta,5beta-乙桥-10bH-吡啶并[3,2-b]咔唑-10bbeta,13-二醇 (3R,6S,6aS,7R,7aS,10S,12aS,13R,13aR,14S,15R)-1-乙基十四氢-12a,14-二羟基-6-甲氧基-3-甲基-8H-13,3,6a-亚乙基-7,10-甲桥氧杂卓并[3,4-i]-1-苯并氮杂环辛四烯-8-酮 (2S,4aR,8aR)-2-甲基八氢-4(1H)-喹啉酮 (2R,4R,4As,8As)-rel-4-乙炔基十氢-1,2-二甲基-4-喹啉醇 (4aS,5R,8aR)-1-(tert-butoxy)carbonyl-2-oxo-5-(triisopropylsilyloxymethyl)decahydroquinoline trans-(+/-)-1-n-propyl-7-oxodecahydroquinoline 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aβH)-benzo[c]quinolizin-3-one 3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aαH)-benzo[c]quinolizin-3-one 3,4,4a,5,6,7,8-heptahydro-8a-hydrodioxy-2(1H)-quinolinone [2-(2,3-dichloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone (octahydro-quinolin-1-yl)-(2-pyridin-3-yl-thiazol-4-yl)-methanone 2-methylperhydrothiazolo<2,3-j>quinoline 2,4-dichloro-N-[5-((4aRS,8aSR)-octahydroquinoline-1-carbonyl)pyridin-2-yl]benzamide (4aR*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-methylquinoline (4aS*,5S*,8aR*)-1,2,3,4,4a,5,6,7,8,8a-Decahydro-5-<(dimethylphenylsilyl)methyl>-1-(methoxycarbonyl)quinoline (2S,3R,4aS,5R,8aR)-1-(tert-butoxy)carbonyl-3-hydroxy-2-methyl-5-(triisopropylsilyloxymethyl)decahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-5-methylene-2-propyldecahydroquinoline (+/-)-(2SR,4aRS,8aRS)-1-tert-butyloxycarbonyl-2-propyldecahydroquinolin-5-one cis-4-[4-(octahydro-quinoline-1(2H)-ylcarbonyl)-thiophen-2-yl]-piperidine-1-carboxylic acid amide lepadin E (+)-lepadin D cis-(octahydro-quinolin-1(2H)-yl)-(5-piperidin-4-yl-thiophen-3-yl)-methanone 4-methyl-6-(3-methyl-2-thienyl)-4,5,6,7-tetrahydroquinolin-5-one 2,2,4,8-tetramethyldecahydroquinoline 10-oxo-2,5;5,9-diseco-A-dinor-strychnidine-2,5-dioic acid strychnidine-2,3,10-trione 3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one 17a-methyl-3-tetrazolo-17a-aza-D-homo-3,5-androstadien-17-one methyl 4-oxooctahydroquinoline-1(2H)-carboxylate decahydro-2-oxo-8-quinolinepropanoic acid ethyl ester 1-octahydro[1]quinolyl-propan-2-ol